-
Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030
16 Apr 2024 17:01 GMT
… Valley/iStock, Sundry Photography
Boehringer Ingelheim announced an ambitious pipeline strategy … metabolic diseases. In 2023, the FDA granted the company five fast … board of managing directors at Boehringer Ingelheim, said in a statement. “We …
-
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16 Apr 2024 09:11 GMT
… , regulators awarded five additional FDA fast-track designations and one … FDA breakthrough therapy designation in … are adjusted for currency effects
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active …
-
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16 Apr 2024 08:35 GMT
… , regulators awarded five additional FDA fast-track designations and one … FDA breakthrough therapy designation in … are adjusted for currency effects
Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active …
-
FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Safety Signals
15 Apr 2024 15:16 GMT
… on Monday announced that the FDA has slapped a clinical hold … it will work with the FDA to find a way to … .
Also targeting the market is Boehringer Ingelheim, which last month pledged up …
-
Asthma Attack and Allergies: Rising Costs Impacting Patients
17 Apr 2024 21:05 GMT
… .
In March, three companies – GSK, Boehringer Ingelheim, and AstraZeneca – announced a $35 … Global Initiative for Asthma, the FDA hasn’t approved ICS-formoterol … said. “There are challenges with FDA approval and insurance companies being …
-
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
17 Apr 2024 14:44 GMT
… these data to the FDA and other global health … has previously earned the FDA’s Fast Track designation for … against.
Last month, the FDA approved Novo Nordisk’s Wegovy … disease.
In February 2024, Boehringer Ingelheim’s obesity hopeful survodutide demonstrated …
-
MASH Innovator Drug Partnerships Surge Over $2.5 Billion In 2024YTD, Reveals GlobalData
17 Apr 2024 11:39 GMT
… first drug approved by the FDA for MASH in March 2024 … returned in light of the FDA approval of Madrigal’s Rezdiffra … deal value.
In January 2024, Boehringer Ingelheim signed a partnership deal worth …
-
OTC Product Roundup: Allergies
16 Apr 2024 18:12 GMT
… Care
FDA Approves Resmetirom as First-Ever Treatment For MASH
Boehringer Ingelheim to … Costs at $35 Per Month
FDA Grants Breakthrough Therapy Designation to … for Generalized Anxiety Disorder
Breaking: FDA Clears Dexcom Stelo, First OTC …
-
Jardiance and Ofev propel Boehringer’s human pharma sales
16 Apr 2024 16:27 GMT
Boehringer Ingelheim reported robust sales in 2023, … US Food and Drug Administration (FDA) approved Boehringer and Eli Lilly … and heart failure. Ofev gained FDA approval for the treatment of … 2014. Following this, Boehringer secured FDA approval for Ofev for the …
-
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
16 Apr 2024 14:09 GMT
… as Boehringer Ingelheim’s Cyltezo, Hyrimoz has not yet won the FDA’s … formulation and also has the FDA’s interchangeability designation.
However, according …